Calliditas Therapeutics AB (CALT)
22.03
-0.11
(-0.48%)
USD |
NASDAQ |
May 16, 16:00
22.14
+0.11
(+0.50%)
After-Hours: 20:00
Calliditas Therapeutics Total Liabilities (Quarterly): 151.43M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 151.43M |
| September 30, 2023 | 115.39M |
| June 30, 2023 | 110.94M |
| December 31, 2022 | 113.86M |
| September 30, 2022 | 71.13M |
| June 30, 2022 | 72.15M |
| March 31, 2022 | 51.24M |
| December 31, 2021 | 49.92M |
| September 30, 2021 | 54.38M |
| June 30, 2021 | 30.62M |
| March 31, 2021 | 29.20M |
| December 31, 2020 | 25.35M |
| Date | Value |
|---|---|
| September 30, 2020 | 7.071M |
| June 30, 2020 | 6.628M |
| March 31, 2020 | 5.957M |
| December 31, 2019 | 6.114M |
| September 30, 2019 | 3.156M |
| June 30, 2019 | 5.120M |
| March 31, 2019 | 3.184M |
| December 31, 2018 | 3.368M |
| September 30, 2018 | 3.181M |
| June 30, 2018 | 6.570M |
| March 31, 2018 | 3.848M |
| December 31, 2017 | 3.560M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.156M
Minimum
Sep 2019
151.43M
Maximum
Dec 2023
50.54M
Average
40.27M
Median
Total Liabilities (Quarterly) Benchmarks
| DBV Technologies SA | 34.24M |
| Cellectis SA | 249.58M |
| Adaptimmune Therapeutics PLC | 243.10M |
| Akari Therapeutics PLC | 4.584M |
| Biodexa Pharmaceuticals Plc | 7.470M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 184.69M |
| Shareholders Equity (Quarterly) | 33.26M |
| Debt to Equity Ratio | 2.806 |
| Current Ratio | 3.132 |
| Net Debt Paydown Yield | -1.46% |